ENSC Ensysce Biosciences, Inc.

NASDAQ
$0.41

Ensysce Biosciences, Inc. (ENSC) is expected to report earnings on November 12, 2026, after the market close. The consensus earnings estimate is a loss of $0.19 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +21.6% since its last earnings release on August 13, 2026.

Ensysce Biosciences Beat Consensus Estimates
Thursday, August 13, 2026 · 4:15 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 12
Thursday · 4:15 PM ET
Earnings Whisper
-
vs ($0.19)
Rev est $1.18M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $0.41

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Ensysce Biosciences, Inc.

Ensysce Biosciences is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is involved in developing tamper-proof opioids which prevent both drug abuse and overdoses. Ensysce Biosciences, formerly known as Leisure Acquisition Corp., is based in SAN DIEGO.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.